Vijay Alagappan

Statistics

Publications

Citations

1.4K

H-Index

Active since

2009

Affiliations

AstraZeneca (United States)(Current)

Novartis (United States)

AstraZeneca (Sweden)

AstraZeneca (Spain)

St. Joseph’s Healthcare Hamilton

Vijay Alagappan is an author at AstraZeneca (United States) specializing in pharmacotherapy, pulmonology, and chronic obstructive pulmonary disease pharmacotherapy.

Publications per year

2009–2022

Publications

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study

Claus Vogelmeier, Eric Bateman, John Pallante et al. · The Lancet Respiratory Medicine · 2012 · 315 citations

Medicine, Pharmacology, Pharmacotherapy +12

96‐Channel receive‐only head coil for 3 Tesla: Design optimization and evaluation

Graham C. Wiggins, Jon̈athan R. Polimeni, Andreas Potthast et al. · Magnetic Resonance in Medicine · 2009 · 274 citations · Full text

Medicine, Biomedical Engineering, Radiology +15

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

Hugh Montgomery, Richard Hobbs, Francisco Padilla et al. · The Lancet Respiratory Medicine · 2022 · 227 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +5

Efficacy and safety of NVA237 <i>versus</i> placebo and tiotropium in patients with COPD: the GLOW2 study

Edward Kerwin, Jacques Hébert, Nicola Gallagher et al. · European Respiratory Journal · 2012 · 209 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study

Ronald Dahl, Kenneth R. Chapman, Michael Rudolf et al. · Respiratory Medicine · 2013 · 91 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

1–5 of 13